Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02922166
Recruitment Status : Active, not recruiting
First Posted : October 4, 2016
Last Update Posted : June 10, 2019
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Azevan Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE September 29, 2016
First Posted Date  ICMJE October 4, 2016
Last Update Posted Date June 10, 2019
Actual Study Start Date  ICMJE February 3, 2017
Actual Primary Completion Date May 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 30, 2016)
Change in startle reflex between SRX246 and Placebo [ Time Frame: up to 7 days ]
Subjects will be exposed to none (N), predictable (P) and unpredictable (U) acoustic and electric shocks.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 30, 2016)
  • Change in emotional expression recognition between SRX246 and Placebo [ Time Frame: up to 7 days ]
    Subjects will be shown pictures of faces exhibiting anger, disgust, fear, happiness, sadness and surprise.
  • Change in State Anxiety Scale between SRX246 and Placebo [ Time Frame: up to 7 days ]
    Subjects will rate their anxiety level during assessments using a self-administered rating scale.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
Official Title  ICMJE Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Brief Summary To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.
Detailed Description The study will use a double-blind, cross-over design in which each subject will receive placebo and SRX246 for 5-7 days before testing (given in counter-balanced order). The study will examine the effect of the drug on the potentiation of startle using a well-established paradigm that involves anticipation of no-shock, predictable shock, and unpredictable shock. Drug effects on emotion recognition will also be explored.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Fear
  • Anxiety
Intervention  ICMJE
  • Drug: SRX246
    oral capsule
  • Drug: Placebo
    oral capsule
Study Arms  ICMJE
  • Experimental: SRX246
    SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
    Intervention: Drug: SRX246
  • Placebo Comparator: Placebo
    Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 6, 2019)
36
Original Estimated Enrollment  ICMJE
 (submitted: September 30, 2016)
47
Estimated Study Completion Date  ICMJE December 2019
Actual Primary Completion Date May 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male and female volunteers, ages 21-50, inclusive.
  • Subjects able to give their consent and have signed informed consent forms indicating that they understand the purpose and procedures of the study and are willing to participate in the study procedures and restrictions.
  • Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).

Exclusion Criteria:

  • Non-English speakers
  • Current or history of Axis I psychiatric disorder(s) as identified with the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np) and clinical evaluation.
  • Active or history of active suicidal ideation.
  • Lifetime alcohol or drug dependence according to the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np).
  • All prescription and non-prescription medications and herbal remedies are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and until at least 7 days or 5 half-lives (whichever is longer) after last dose of study medication, except hormonal contraceptives in females.
  • Clear evidence of a first-degree relative with history of psychosis, bipolar disorder or major depression as determined by the family history method; specifically, participant will know diagnosis or treatment in order to confirm presence of disorder.
  • Subject is currently participating in another clinical trial in which (s)he is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month.
  • Current evidence or history of significant medical illness or organic brain impairment, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), diabetes insipidus (DI), stroke, epilepsy, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere with the action, absorption, distribution, metabolism, or excretion of SRX246, or influence psychophysiological responses.
  • Current evidence of median nerve entrapment or carpal tunnel syndrome.
  • Any laboratory abnormality that in the investigators' judgment is considered to be clinically significant (ECG, TSH, LFT, etc.).
  • Abnormal urine specific gravity (below 1.00 or above 1.03) as documented by urine sample refractometry.
  • Subject who has resting blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
  • Subject who has resting pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
  • Consumption of illicit substances or positive urine toxicology screen throughout the study.
  • Pregnancy, lactating/breastfeeding, or positive pregnancy test.
  • A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to SRX246, or allergy to gelatin.
  • Lack of measurable startle response (3 times the baseline EMG activity) for all 9 startles used during the habituation visit.
  • Subjects who would be noncompliant with the visit schedule or study procedures. Possible noncompliance may include planned vacations or planned hospitalizations during the study.
  • For women who are able to get pregnant and men who are able to father a child, unwillingness to use at least two effective birth control methods for 15 days prior to the time they enroll in the study, and for 15 days after their last exposure to the study drug. Effective methods of contraception for this study include:

    1. hormonal contraception (birth control pills, injected hormones or vaginal ring),
    2. intrauterine device,
    3. barrier methods (condom or diaphragm) combined with spermicide, and
    4. surgical sterilization (hysterectomy, tubal ligation, or vasectomy).
  • Employee of NIMH or an immediate family member who is a NIMH employee
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02922166
Other Study ID Numbers  ICMJE AVN012
T-M-1970 ( Other Identifier: National Institute of Mental Health )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Data and samples will be shared with Azevan Pharmaceuticals Inc., its affiliates and research partners working with Azevan Pharmaceuticals Inc.
Responsible Party Azevan Pharmaceuticals
Study Sponsor  ICMJE Azevan Pharmaceuticals
Collaborators  ICMJE National Institute of Mental Health (NIMH)
Investigators  ICMJE Not Provided
PRS Account Azevan Pharmaceuticals
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP